NCT00551031: Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects |
|
|
| Completed | 2 | 2098 | US | Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Fluzone®, Split, Inactivated, Trivalent Influenza Vaccine (High-dose), Fluzone® High-dose | Sanofi | Influenza, Myxovirus Infection | 06/08 | 11/08 | | |
NCT01258595: A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age |
|
|
| Completed | 2 | 300 | US | High-Dose Trivalent Inactivated Influenza Vaccine, Fluzone® High-Dose, Trivalent Inactivated Influenza Vaccine, Fluzone® | Sanofi Pasteur, a Sanofi Company | Influenza | 03/11 | 04/11 | | |
NCT01666782: Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy |
|
|
| Completed | 2 | 105 | US | Standard Trivalent Influenza Vaccine, Fluzone, High-Dose Influenza Vaccine, Fluzone High-Dose | Saad Jamshed MD, Sanofi | Cancer, Influenza Viral Infections | 06/15 | 12/15 | | |
